Clarity Pharmaceuticals is a biotechnology business based in Australia. Clarity Pharmaceuticals shares (CU6) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Clarity Pharmaceuticals has a trailing 12-month revenue of around $9.5 million. If you're looking to buy shares, check out the steps below.
To buy shares listed in Australia such as Clarity Pharmaceuticals, you'll need to sign up to a broker with access to the ASX. Our table can help you compare share trading platforms and choose. Then follow these steps.
Our top pick for
Best for beginner
Our top pick for
Education & learning
Our top pick for
Australian stocks
| 52-week range | $0.675 - $2.98 |
|---|---|
| 50-day moving average | $2.4856 |
| 200-day moving average | $1.4575 |
| Target price | $3.08 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.12 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$2.65
| 1 week (2024-03-08) | -6.03% |
|---|---|
| 1 month (2024-02-16) | 4.74% |
| 3 months (2023-12-18) | 60.61% |
| 6 months (2023-09-18) | 115.45% |
| 1 year (2023-03-17) | 227.16% |
|---|---|
| 2 years (2022-03-18) | 381.82% |
| Revenue TTM | $9.5 million |
|---|---|
| Gross profit TTM | $9.8 million |
| Return on assets TTM | -27.67% |
| Return on equity TTM | -45.33% |
| Profit margin | 0% |
| Book value | 0.202 |
| Market capitalisation | $732.8 million |
TTM: trailing 12 months
We're not expecting Clarity Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Clarity Pharmaceuticals's shares have ranged in value from as little as $0.675 up to $2.98. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Clarity Pharmaceuticals's is 1.318. This would suggest that Clarity Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively speaking, a higher risk (but potentially also market-beating returns).
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.
AMP Ltd Preferred
AUD103.63
ANZ Group Holdings Ltd. Pfd.
AUD101.63
ANZ Group Holdings Ltd. Pfd.
AUD102.96
Challenger Ltd Preferred
AUD104.64
Macquarie Bank Ltd Pref
AUD104.75
Macquarie Group Ltd Pref C
AUD102.35
Macquarie Group Preferred
AUD101.66
Macquarie Group Limited
AUD104.90
Suncorp Group Ltd Pref
AUD100.90
Westpac Banking Corp Pref
AUD101.90
Whitefield Ltd Pref B
AUD99.25
Explore Spaceship's US Investing service: low entry cost with a focus, but limited trading options.
Everything we know about the Maverick Minerals IPO, plus information on how to buy in.
Steps to owning and managing LTR Pharma shares.
We used Finder's proprietary algorithm to find Australian-listed companies that have strong fundamentals and have a share price under $5.
We used a proprietary algorithm to find the a list of ASX penny stocks that should be on your watchlist in 2024.
Looking for the best performing stocks in Australia? We update this list weekly.
Here are our algorithm-selected 20 Aussie stocks worth watching in 2024.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Following a couple of lean years for dividend investors, here are 20 ideas you could consider in your portfolio.
These ETFs have the lowest fees on the market, but does that make them the best?